berberine has been researched along with Colitis in 39 studies
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study focuses on constructing of an anti-inflammatory drug delivery system by encapsulation of berberine in the β-glucan nanoparticles and evaluates its effect on treating ulcerative colitis." | 8.12 | Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis. ( Chen, Q; Fan, Y; Huang, J; Liang, M; Long, H; Wang, Y; Wang, Z; Wu, C; Xu, Y, 2022) |
| "The present study explored the synergetic effects of berberine and 6-shogaol, the primary components of Coptidis Rhizoma and Zingiberis Rhizoma, respectively, on intestinal inflammation and intestinal flora in mice with ulcerative colitis to reveal the effect and mechanism of cold-heat combination in the treatment of ulcerative colitis." | 8.12 | [Experimental study on effects of berberine combined with 6-shogaol on intestinal inflammation and flora in mice with ulcerative colitis]. ( Chen, ZG; Li, JT; Wei, HL; Yan, SG, 2022) |
| " In this study, the effects and the mechanism of BBR on colon cancer were investigated in an azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colitis-associated carcinogenesis mice model." | 8.12 | Pre-Administration of Berberine Exerts Chemopreventive Effects in AOM/DSS-Induced Colitis-Associated Carcinogenesis Mice via Modulating Inflammation and Intestinal Microbiota. ( Deng, J; Han, L; Li, Y; Shi, J; Wang, H; Yan, Y; Yuan, X; Zhang, H; Zhao, H; Zhao, L; Zhao, Y; Zou, F, 2022) |
| " Berberine can reduce colorectal adenoma recurrence and inhibit colorectal carcinogenesis." | 8.12 | Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora. ( Chang, J; Geng, Z; Hao, X; Liu, J; Tan, X; Wang, Z; Yan, S, 2022) |
| "Berberine (BBR), a compound long used in traditional Chinese medicine, has been reported to have therapeutic effects in treating ulcerative colitis (UC), attributed to its anti-inflammatory properties and restorative potential of tight junctions (TJs)." | 8.02 | Berberine inhibits dendritic cells differentiation in DSS-induced colitis by promoting Bacteroides fragilis. ( Hassan, S; Wang, Y; Xu, G; Xu, Y; Zhang, M; Zheng, C; Zhou, L; Zou, X, 2021) |
| "Berberine, initially isolated from Rhizoma Coptidis (Huanglian in Chinese), is a drug used to treat gastrointestinal disorders such as colitis." | 7.96 | Circadian pharmacological effects of berberine on chronic colitis in mice: Role of the clock component Rev-erbα. ( Gao, L; Lin, Y; Wang, S; Wu, B; Yang, Z; Zhou, Z, 2020) |
| "Berberine (BBR), a naturally-occurring isoquinoline alkaloid isolated from several Chinese herbal medicines, has been widely used for the treatment of dysentery and colitis." | 7.96 | Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-κB pathway. ( Ai, G; Chen, J; Huang, X; Li, C; Li, Y; Lin, G; Lin, Z; Liu, Y; Lu, Q; Luo, C; Su, Z; Tan, L; Wang, Y; Xian, Y; Xie, J; Zeng, H, 2020) |
| " At present, researches have presented obesity is a high-risk factor for colitis, and berberine shows positive therapeutic effect on colitis." | 7.96 | Regulation of MFN2 by berberine alleviates obesity exacerbated colitis. ( Chen, Y; Liu, F; Wen, S; Zheng, Y, 2020) |
| "Berberine has been reported to have protective effects in colitis treatment." | 7.88 | Berberine inhibits macrophage M1 polarization via AKT1/SOCS1/NF-κB signaling pathway to protect against DSS-induced colitis. ( Chen, C; Fang, X; Ge, C; Hua, W; Liu, C; Liu, X; Liu, Y; Tao, Y; Wei, Q; Zhao, Z; Zhu, Y, 2018) |
| " Berberine (BBR), a compound long used in traditional Chinese medicines, has been reported to have therapeutic effects in treating experimental colitis." | 7.81 | Berberine ameliorates TNBS induced colitis by inhibiting inflammatory responses and Th1/Th17 differentiation. ( Chen, G; Cheng, W; Li, C; Li, S; Niu, X; Wang, Z; Xi, Y; Zhao, Q; Zhong, J, 2015) |
| "The anti-inflammatory effect of berberine was evaluated in murine model of acute experimental colitis induced by dextran sulfate sodium (DSS)." | 7.78 | Suppressive effect of berberine on experimental dextran sulfate sodium-induced colitis. ( Hong, T; Lv, CF; Yang, Z; Zhang, Y, 2012) |
| "Berberine, which is a major constituent of the rhizome of Coptidis japonica (CJ), inhibits IL-8 production in colonic epithelial cells and improves 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice." | 7.76 | Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB activation. ( Hyun, YJ; Kim, DH; Lee, IA, 2010) |
| " The aims of this study were to examine the effect of berberine on the mucosal healing process and to investigate whether berberine can inhibit the increased production of interleukin-8 in trinitrobenzene sulfonic acid-induced colitis in rats." | 7.70 | The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. ( Mineshita, S; Zhou, H, 2000) |
| "Colitis is an inflammatory bowel disease with chronic nature." | 6.66 | Berberine Administration in Treatment of Colitis: A Review. ( Ashrafizadeh, M; Farkhondeh, T; Mohammadinejad, R; Najafi, M; Samarghandian, S, 2020) |
| "Collectively, BBR has the capacity to treat DSS-induced colitis in rats through the regulation of gut microbiota associated tryptophan metabolite to activate AhR, which can greatly improve the disrupted gut barrier function." | 5.62 | Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites. ( Dong, S; Du, W; Jing, W; Liu, J; Lu, H; Luo, H; Luo, X; Wang, S; Wang, Y; Wei, B; Yang, L, 2021) |
| " In summary, BB exerted similar effect to its analogue BBR and positive control in attenuating DSS-induced UC with much lower dosage and similar mechanism." | 5.48 | Berberrubine attenuates mucosal lesions and inflammation in dextran sodium sulfate-induced colitis in mice. ( Chen, JP; Huang, YF; Li, HL; Qu, C; Su, ZR; Xu, LQ; Xu, YF; Yi, TG; Yu, XT; Zeng, HF; Zhang, XJ; Zheng, L, 2018) |
| "Colitis was induced by two cycles of 2." | 5.43 | Berberine ameliorates chronic relapsing dextran sulfate sodium-induced colitis in C57BL/6 mice by suppressing Th17 responses. ( Bian, ZX; Fatima, S; Hu, DD; Lee, NP; Li, YH; Lin, CY; Mu, HX; Xiao, HT, 2016) |
| "Berberine is an herbal alkaloid with various biological activities, including anti-inflammatory and antidepressant effects." | 5.42 | Berberine is a dopamine D1- and D2-like receptor antagonist and ameliorates experimentally induced colitis by suppressing innate and adaptive immune responses. ( Kaneko, A; Kawano, M; Matsushita, S; Takagi, R, 2015) |
| "Berberine was administered through gavage to mice with established DSS-induced intestinal injury and colitis." | 5.38 | Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. ( Cao, H; Chaturvedi, R; Israel, DA; Liu, L; Peek, RM; Polk, DB; Shi, Y; Wang, B; Wang, L; Washington, MK; Wilson, KT; Yan, F, 2012) |
| " In this study, the effects and the mechanism of BBR on colon cancer were investigated in an azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colitis-associated carcinogenesis mice model." | 4.12 | Pre-Administration of Berberine Exerts Chemopreventive Effects in AOM/DSS-Induced Colitis-Associated Carcinogenesis Mice via Modulating Inflammation and Intestinal Microbiota. ( Deng, J; Han, L; Li, Y; Shi, J; Wang, H; Yan, Y; Yuan, X; Zhang, H; Zhao, H; Zhao, L; Zhao, Y; Zou, F, 2022) |
| " Berberine can reduce colorectal adenoma recurrence and inhibit colorectal carcinogenesis." | 4.12 | Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora. ( Chang, J; Geng, Z; Hao, X; Liu, J; Tan, X; Wang, Z; Yan, S, 2022) |
| "The present study explored the synergetic effects of berberine and 6-shogaol, the primary components of Coptidis Rhizoma and Zingiberis Rhizoma, respectively, on intestinal inflammation and intestinal flora in mice with ulcerative colitis to reveal the effect and mechanism of cold-heat combination in the treatment of ulcerative colitis." | 4.12 | [Experimental study on effects of berberine combined with 6-shogaol on intestinal inflammation and flora in mice with ulcerative colitis]. ( Chen, ZG; Li, JT; Wei, HL; Yan, SG, 2022) |
| "This study focuses on constructing of an anti-inflammatory drug delivery system by encapsulation of berberine in the β-glucan nanoparticles and evaluates its effect on treating ulcerative colitis." | 4.12 | Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis. ( Chen, Q; Fan, Y; Huang, J; Liang, M; Long, H; Wang, Y; Wang, Z; Wu, C; Xu, Y, 2022) |
| "Berberine (BBR), a compound long used in traditional Chinese medicine, has been reported to have therapeutic effects in treating ulcerative colitis (UC), attributed to its anti-inflammatory properties and restorative potential of tight junctions (TJs)." | 4.02 | Berberine inhibits dendritic cells differentiation in DSS-induced colitis by promoting Bacteroides fragilis. ( Hassan, S; Wang, Y; Xu, G; Xu, Y; Zhang, M; Zheng, C; Zhou, L; Zou, X, 2021) |
| "Berberine, initially isolated from Rhizoma Coptidis (Huanglian in Chinese), is a drug used to treat gastrointestinal disorders such as colitis." | 3.96 | Circadian pharmacological effects of berberine on chronic colitis in mice: Role of the clock component Rev-erbα. ( Gao, L; Lin, Y; Wang, S; Wu, B; Yang, Z; Zhou, Z, 2020) |
| " At present, researches have presented obesity is a high-risk factor for colitis, and berberine shows positive therapeutic effect on colitis." | 3.96 | Regulation of MFN2 by berberine alleviates obesity exacerbated colitis. ( Chen, Y; Liu, F; Wen, S; Zheng, Y, 2020) |
| "Berberine (BER), a natural isoquinoline alkaloid, has been demonstrated to have appreciable anticolitis effects." | 3.96 | Anticolitic Effect of Berberine in Rat Experimental Model: Impact of PGE2/p38 MAPK Pathways. ( Abdel Moneim, AE; Habotta, OA; Hu, L; Jia, L; Liu, J; Xue, K, 2020) |
| "Berberine has been reported to have protective effects in colitis treatment." | 3.88 | Berberine inhibits macrophage M1 polarization via AKT1/SOCS1/NF-κB signaling pathway to protect against DSS-induced colitis. ( Chen, C; Fang, X; Ge, C; Hua, W; Liu, C; Liu, X; Liu, Y; Tao, Y; Wei, Q; Zhao, Z; Zhu, Y, 2018) |
| " Berberine (BBR), a compound long used in traditional Chinese medicines, has been reported to have therapeutic effects in treating experimental colitis." | 3.81 | Berberine ameliorates TNBS induced colitis by inhibiting inflammatory responses and Th1/Th17 differentiation. ( Chen, G; Cheng, W; Li, C; Li, S; Niu, X; Wang, Z; Xi, Y; Zhao, Q; Zhong, J, 2015) |
| "The anti-inflammatory effect of berberine was evaluated in murine model of acute experimental colitis induced by dextran sulfate sodium (DSS)." | 3.78 | Suppressive effect of berberine on experimental dextran sulfate sodium-induced colitis. ( Hong, T; Lv, CF; Yang, Z; Zhang, Y, 2012) |
| "Berberine, which is a major constituent of the rhizome of Coptidis japonica (CJ), inhibits IL-8 production in colonic epithelial cells and improves 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice." | 3.76 | Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB activation. ( Hyun, YJ; Kim, DH; Lee, IA, 2010) |
| " The aims of this study were to examine the effect of berberine on the mucosal healing process and to investigate whether berberine can inhibit the increased production of interleukin-8 in trinitrobenzene sulfonic acid-induced colitis in rats." | 3.70 | The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. ( Mineshita, S; Zhou, H, 2000) |
| "Forty-two patients with cervical cancer were randomized to a trial group (n = 21) and control group (n = 21)." | 2.75 | Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy. ( Chen, ZT; Hao, P; Hu, YD; Li, DZ; Li, GH; Pu, P; Wan, JQ; Wang, DL; Wang, J; Wang, WD; Xu, XQ; Zhou, YB; Zhu, B, 2010) |
| "Berberine (BBR) is an effective drug for UC treatment." | 1.72 | Berberine ameliorates DSS-induced intestinal mucosal barrier dysfunction through microbiota-dependence and Wnt/β-catenin pathway. ( Dong, Y; Fan, H; Fu, Y; Gui, Y; Guo, W; Hu, D; Jiang, F; Kang, Z; Li, J; Li, M; Luo, S; Sarapultsev, A; Shou, Z; Wang, H; Zhang, G; Zhang, Z; Zhou, H; Zhu, R, 2022) |
| "Collectively, BBR has the capacity to treat DSS-induced colitis in rats through the regulation of gut microbiota associated tryptophan metabolite to activate AhR, which can greatly improve the disrupted gut barrier function." | 1.62 | Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites. ( Dong, S; Du, W; Jing, W; Liu, J; Lu, H; Luo, H; Luo, X; Wang, S; Wang, Y; Wei, B; Yang, L, 2021) |
| "Chronic inflammation is known to promote carcinogenesis; Dicer heterozygous mice are more likely to develop colitis-associated tumors." | 1.56 | Rescuing Dicer expression in inflamed colon tissues alleviates colitis and prevents colitis-associated tumorigenesis. ( Chen, X; Gao, J; He, Q; He, ZW; Jin, Y; Lei, Y; Liu, H; Ou, R; Song, G; Tang, KF; Wang, WY; Wang, Z; Wei, LJ; Wu, X; Xu, Y; Yang, W; Zhang, Z; Zhong, S; Zhou, L, 2020) |
| " In summary, BB exerted similar effect to its analogue BBR and positive control in attenuating DSS-induced UC with much lower dosage and similar mechanism." | 1.48 | Berberrubine attenuates mucosal lesions and inflammation in dextran sodium sulfate-induced colitis in mice. ( Chen, JP; Huang, YF; Li, HL; Qu, C; Su, ZR; Xu, LQ; Xu, YF; Yi, TG; Yu, XT; Zeng, HF; Zhang, XJ; Zheng, L, 2018) |
| "Colitis was induced by two cycles of 2." | 1.43 | Berberine ameliorates chronic relapsing dextran sulfate sodium-induced colitis in C57BL/6 mice by suppressing Th17 responses. ( Bian, ZX; Fatima, S; Hu, DD; Lee, NP; Li, YH; Lin, CY; Mu, HX; Xiao, HT, 2016) |
| "Berberine is an herbal alkaloid with various biological activities, including anti-inflammatory and antidepressant effects." | 1.42 | Berberine is a dopamine D1- and D2-like receptor antagonist and ameliorates experimentally induced colitis by suppressing innate and adaptive immune responses. ( Kaneko, A; Kawano, M; Matsushita, S; Takagi, R, 2015) |
| "Berberine was administered through gavage to C57BL/6 mice with established CDI-induced intestinal injury and colitis." | 1.42 | Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment. ( Liu, W; Lv, Z; Peng, G; Su, J; Xu, H, 2015) |
| "Berberine was administered through gavage to mice with established DSS-induced intestinal injury and colitis." | 1.38 | Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. ( Cao, H; Chaturvedi, R; Israel, DA; Liu, L; Peek, RM; Polk, DB; Shi, Y; Wang, B; Wang, L; Washington, MK; Wilson, KT; Yan, F, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.56) | 29.6817 |
| 2010's | 12 (30.77) | 24.3611 |
| 2020's | 26 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, C | 1 |
| Wang, Y | 9 |
| Xu, Y | 5 |
| Zhou, L | 2 |
| Hassan, S | 1 |
| Xu, G | 1 |
| Zou, X | 1 |
| Zhang, M | 2 |
| Deng, J | 1 |
| Zhao, L | 2 |
| Yuan, X | 1 |
| Li, Y | 6 |
| Shi, J | 1 |
| Zhang, H | 1 |
| Zhao, Y | 1 |
| Han, L | 1 |
| Wang, H | 5 |
| Yan, Y | 2 |
| Zhao, H | 1 |
| Zou, F | 1 |
| Zhao, X | 1 |
| Cui, D | 1 |
| Yuan, W | 1 |
| Chen, C | 2 |
| Liu, Q | 1 |
| Dong, Y | 1 |
| Fan, H | 1 |
| Zhang, Z | 4 |
| Jiang, F | 1 |
| Li, M | 2 |
| Zhou, H | 3 |
| Guo, W | 1 |
| Kang, Z | 1 |
| Gui, Y | 1 |
| Shou, Z | 1 |
| Li, J | 2 |
| Zhu, R | 1 |
| Fu, Y | 2 |
| Sarapultsev, A | 1 |
| Luo, S | 1 |
| Zhang, G | 3 |
| Hu, D | 1 |
| Chen, H | 2 |
| Ye, C | 1 |
| Cai, B | 1 |
| Zhang, F | 1 |
| Wang, X | 1 |
| Zhang, J | 1 |
| Guo, Y | 1 |
| Yao, Q | 1 |
| Yan, S | 1 |
| Chang, J | 1 |
| Hao, X | 1 |
| Liu, J | 4 |
| Tan, X | 1 |
| Geng, Z | 1 |
| Wang, Z | 10 |
| Li, L | 1 |
| Wu, K | 1 |
| Peng, L | 1 |
| Liang, Y | 2 |
| Han, Q | 1 |
| Deng, LR | 1 |
| Zou, M | 1 |
| Tang, HZ | 1 |
| Huang, CY | 1 |
| Chen, FJ | 1 |
| Tomlinson, B | 1 |
| Li, YH | 2 |
| Wei, HL | 1 |
| Li, JT | 1 |
| Chen, ZG | 1 |
| Yan, SG | 1 |
| Chen, S | 1 |
| Chen, Z | 1 |
| Hao, W | 1 |
| Yuan, Q | 1 |
| Gao, C | 2 |
| Wu, X | 2 |
| Wang, S | 4 |
| Wu, C | 4 |
| Zheng, T | 1 |
| Zou, P | 1 |
| Wang, J | 3 |
| Li, N | 1 |
| Zhang, Y | 3 |
| Dong, Z | 1 |
| Li, X | 1 |
| Xu, S | 1 |
| Li, K | 1 |
| Gao, XJ | 1 |
| Guo, MY | 1 |
| Huang, J | 3 |
| Fan, Y | 3 |
| Long, H | 3 |
| Liang, M | 3 |
| Chen, Q | 3 |
| Luo, Z | 2 |
| Li, Z | 2 |
| Liang, Z | 2 |
| Wang, L | 4 |
| He, G | 2 |
| Wang, D | 2 |
| Shen, L | 2 |
| Ma, X | 2 |
| Geng, F | 2 |
| Liu, W | 3 |
| Liu, H | 3 |
| Li, B | 2 |
| Gao, S | 1 |
| Gao, F | 1 |
| Kong, JW | 1 |
| Wang, ZJ | 1 |
| Zheng, HC | 1 |
| Jiang, XQ | 1 |
| Xu, SJ | 1 |
| Li, SL | 1 |
| Lu, MJ | 1 |
| Dai, ZQ | 1 |
| Chu, FH | 1 |
| Xu, B | 1 |
| Lei, HM | 1 |
| Xu, C | 1 |
| Zhou, W | 1 |
| Hu, H | 1 |
| Takahara, M | 1 |
| Takaki, A | 1 |
| Hiraoka, S | 1 |
| Adachi, T | 1 |
| Shimomura, Y | 1 |
| Matsushita, H | 1 |
| Nguyen, TTT | 1 |
| Koike, K | 1 |
| Ikeda, A | 1 |
| Takashima, S | 1 |
| Yamasaki, Y | 1 |
| Inokuchi, T | 1 |
| Kinugasa, H | 1 |
| Sugihara, Y | 1 |
| Harada, K | 1 |
| Eikawa, S | 1 |
| Morita, H | 1 |
| Udono, H | 1 |
| Okada, H | 1 |
| Li, C | 3 |
| Ai, G | 1 |
| Lu, Q | 1 |
| Luo, C | 2 |
| Tan, L | 1 |
| Lin, G | 1 |
| Liu, Y | 2 |
| Zeng, H | 1 |
| Chen, J | 2 |
| Lin, Z | 1 |
| Xian, Y | 1 |
| Huang, X | 1 |
| Xie, J | 2 |
| Su, Z | 2 |
| Zhou, Z | 1 |
| Lin, Y | 1 |
| Gao, L | 1 |
| Yang, Z | 2 |
| Wu, B | 1 |
| Chen, X | 1 |
| He, ZW | 1 |
| Wei, LJ | 1 |
| Wang, WY | 1 |
| Zhong, S | 1 |
| He, Q | 1 |
| Ou, R | 1 |
| Gao, J | 1 |
| Lei, Y | 1 |
| Yang, W | 1 |
| Song, G | 2 |
| Jin, Y | 1 |
| Tang, KF | 1 |
| Ashrafizadeh, M | 1 |
| Najafi, M | 1 |
| Mohammadinejad, R | 1 |
| Farkhondeh, T | 1 |
| Samarghandian, S | 1 |
| Chen, Y | 1 |
| Zheng, Y | 1 |
| Wen, S | 1 |
| Liu, F | 1 |
| Jia, L | 1 |
| Xue, K | 1 |
| Habotta, OA | 1 |
| Hu, L | 1 |
| Abdel Moneim, AE | 1 |
| Jing, W | 1 |
| Dong, S | 1 |
| Luo, X | 1 |
| Wei, B | 1 |
| Du, W | 1 |
| Yang, L | 1 |
| Luo, H | 1 |
| Lu, H | 1 |
| Huang, Z | 1 |
| Ni, C | 1 |
| Zhang, L | 1 |
| Zhang, T | 1 |
| Ma, C | 1 |
| Zhu, Q | 1 |
| Wang, JJ | 1 |
| Ren, MH | 1 |
| Yang, XJ | 1 |
| Wang, LY | 1 |
| Liu, X | 1 |
| Hua, W | 1 |
| Wei, Q | 1 |
| Fang, X | 1 |
| Zhao, Z | 1 |
| Ge, C | 1 |
| Liu, C | 1 |
| Tao, Y | 1 |
| Zhu, Y | 1 |
| Yu, XT | 1 |
| Xu, YF | 1 |
| Huang, YF | 1 |
| Qu, C | 1 |
| Xu, LQ | 1 |
| Su, ZR | 1 |
| Zeng, HF | 1 |
| Zheng, L | 1 |
| Yi, TG | 1 |
| Li, HL | 1 |
| Chen, JP | 1 |
| Zhang, XJ | 1 |
| Zhong, W | 1 |
| Wang, W | 1 |
| Hu, S | 1 |
| Yuan, J | 1 |
| Zhang, B | 1 |
| Hu, T | 1 |
| Lv, Z | 1 |
| Peng, G | 1 |
| Xu, H | 1 |
| Su, J | 1 |
| Xi, Y | 1 |
| Li, S | 1 |
| Zhao, Q | 1 |
| Cheng, W | 1 |
| Zhong, J | 1 |
| Niu, X | 1 |
| Chen, G | 1 |
| Kawano, M | 1 |
| Takagi, R | 1 |
| Kaneko, A | 1 |
| Matsushita, S | 1 |
| Xiao, HT | 1 |
| Hu, DD | 1 |
| Fatima, S | 1 |
| Lin, CY | 1 |
| Mu, HX | 1 |
| Lee, NP | 1 |
| Bian, ZX | 1 |
| Li, GH | 1 |
| Wang, DL | 1 |
| Hu, YD | 1 |
| Pu, P | 1 |
| Li, DZ | 1 |
| Wang, WD | 1 |
| Zhu, B | 1 |
| Hao, P | 1 |
| Xu, XQ | 1 |
| Wan, JQ | 1 |
| Zhou, YB | 1 |
| Chen, ZT | 1 |
| Lee, IA | 1 |
| Hyun, YJ | 1 |
| Kim, DH | 1 |
| Yan, F | 1 |
| Shi, Y | 1 |
| Cao, H | 2 |
| Liu, L | 1 |
| Washington, MK | 1 |
| Chaturvedi, R | 1 |
| Israel, DA | 1 |
| Wang, B | 1 |
| Peek, RM | 1 |
| Wilson, KT | 1 |
| Polk, DB | 1 |
| Hong, T | 1 |
| Lv, CF | 1 |
| Mineshita, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders[NCT02983188] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2018-04-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for berberine and Colitis
| Article | Year |
|---|---|
Berberine Administration in Treatment of Colitis: A Review.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Berberine; Colitis; Cytokines; Humans; Oxidative St | 2020 |
1 trial available for berberine and Colitis
| Article | Year |
|---|---|
Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy.
Topics: Abdomen; Acute Disease; Acute Radiation Syndrome; Berberine; Carcinoma, Squamous Cell; Colitis; Fema | 2010 |
37 other studies available for berberine and Colitis
| Article | Year |
|---|---|
Berberine inhibits dendritic cells differentiation in DSS-induced colitis by promoting Bacteroides fragilis.
Topics: Animals; Anti-Inflammatory Agents; Bacteroides fragilis; Berberine; Cell Differentiation; Colitis; C | 2021 |
Pre-Administration of Berberine Exerts Chemopreventive Effects in AOM/DSS-Induced Colitis-Associated Carcinogenesis Mice via Modulating Inflammation and Intestinal Microbiota.
Topics: Animals; Azoxymethane; Berberine; Carcinogenesis; Colitis; Colon; Dextran Sulfate; Disease Models, A | 2022 |
Berberine represses Wnt/β-catenin pathway activation via modulating the microRNA-103a-3p/Bromodomain-containing protein 4 axis, thereby refraining pyroptosis and reducing the intestinal mucosal barrier defect induced via colitis.
Topics: Animals; Berberine; beta Catenin; Caco-2 Cells; Cell Cycle Proteins; Colitis; Humans; Mice; MicroRNA | 2022 |
Berberine ameliorates DSS-induced intestinal mucosal barrier dysfunction through microbiota-dependence and Wnt/β-catenin pathway.
Topics: Animals; Berberine; beta Catenin; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Mode | 2022 |
Berberine inhibits intestinal carcinogenesis by suppressing intestinal pro-inflammatory genes and oncogenic factors through modulating gut microbiota.
Topics: Animals; Azoxymethane; Berberine; Carcinogenesis; Colitis; Colon; Dextran Sulfate; Disease Models, A | 2022 |
Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora.
Topics: Animals; Azoxymethane; Berberine; Carcinogenesis; Cell Transformation, Neoplastic; Colitis; Colorect | 2022 |
A Combination of Baicalin and Berberine Hydrochloride Ameliorates Dextran Sulfate Sodium-Induced Colitis by Modulating Colon Gut Microbiota.
Topics: Animals; Berberine; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, | 2022 |
Anemoside B4 protects against chronic relapsing colitis in mice by modulating inflammatory response, colonic transcriptome and the gut microbiota.
Topics: Animals; Berberine; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, | 2022 |
[Experimental study on effects of berberine combined with 6-shogaol on intestinal inflammation and flora in mice with ulcerative colitis].
Topics: Animals; Berberine; Catechols; Claudin-1; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Dise | 2022 |
Targeted delivery of Chinese herb pair-based berberine/tannin acid self-assemblies for the treatment of ulcerative colitis.
Topics: Animals; Antineoplastic Agents; Benzopyrans; Berberine; China; Colitis; Colitis, Ulcerative; Dextran | 2022 |
Effect and Mechanism of Pharmaceutical Excipients on Berberine to Alleviate Ulcerative Colitis via Regulating Gut Microbiota.
Topics: Animals; Berberine; Chitosan; Claudin-2; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disea | 2022 |
Berberine Depresses Inflammation and Adjusts Smooth Muscle to Ameliorate Ulcerative Colitis of Cats by Regulating Gut Microbiota.
Topics: Animals; Berberine; Cats; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Anim | 2022 |
Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis.
Topics: Animals; Anti-Inflammatory Agents; Berberine; beta-Glucans; Colitis; Colitis, Ulcerative; Inflammati | 2022 |
Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis.
Topics: Animals; Anti-Inflammatory Agents; Berberine; beta-Glucans; Colitis; Colitis, Ulcerative; Inflammati | 2022 |
Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis.
Topics: Animals; Anti-Inflammatory Agents; Berberine; beta-Glucans; Colitis; Colitis, Ulcerative; Inflammati | 2022 |
Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis.
Topics: Animals; Anti-Inflammatory Agents; Berberine; beta-Glucans; Colitis; Colitis, Ulcerative; Inflammati | 2022 |
Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis.
Topics: Animals; Anti-Inflammatory Agents; Berberine; beta-Glucans; Colitis; Colitis, Ulcerative; Inflammati | 2022 |
Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis.
Topics: Animals; Anti-Inflammatory Agents; Berberine; beta-Glucans; Colitis; Colitis, Ulcerative; Inflammati | 2022 |
Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis.
Topics: Animals; Anti-Inflammatory Agents; Berberine; beta-Glucans; Colitis; Colitis, Ulcerative; Inflammati | 2022 |
Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis.
Topics: Animals; Anti-Inflammatory Agents; Berberine; beta-Glucans; Colitis; Colitis, Ulcerative; Inflammati | 2022 |
Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis.
Topics: Animals; Anti-Inflammatory Agents; Berberine; beta-Glucans; Colitis; Colitis, Ulcerative; Inflammati | 2022 |
Berberine increases stromal production of Wnt molecules and activates Lgr5
Topics: Animals; Berberine; Colitis; Dextran Sulfate; Disease Models, Animal; Inflammation; Intestinal Mucos | 2022 |
Berberine increases stromal production of Wnt molecules and activates Lgr5
Topics: Animals; Berberine; Colitis; Dextran Sulfate; Disease Models, Animal; Inflammation; Intestinal Mucos | 2022 |
Berberine increases stromal production of Wnt molecules and activates Lgr5
Topics: Animals; Berberine; Colitis; Dextran Sulfate; Disease Models, Animal; Inflammation; Intestinal Mucos | 2022 |
Berberine increases stromal production of Wnt molecules and activates Lgr5
Topics: Animals; Berberine; Colitis; Dextran Sulfate; Disease Models, Animal; Inflammation; Intestinal Mucos | 2022 |
[Therapeutic effect of ursodeoxycholic acid-berberine supramolecular nanoparticles on ulcerative colitis based on supramolecular system induced by weak bond].
Topics: Animals; Berberine; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Dr | 2023 |
Synergistic effect of berberine hydrochloride and dehydrocostus lactone in the treatment of ulcerative colitis: Take gut microbiota as the target.
Topics: Animals; Berberine; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Ga | 2023 |
Berberine improved experimental chronic colitis by regulating interferon-γ- and IL-17A-producing lamina propria CD4
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Berberine; CD4-Positive T-Lymphocyte | 2019 |
Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-κB pathway.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Biotransformation; Cecum; Colitis; Colon; Dextran Sulf | 2020 |
Circadian pharmacological effects of berberine on chronic colitis in mice: Role of the clock component Rev-erbα.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Bone Marrow Cells; Chronic Disease; Circadian Rhythm; | 2020 |
Rescuing Dicer expression in inflamed colon tissues alleviates colitis and prevents colitis-associated tumorigenesis.
Topics: Anastrozole; Animals; Berberine; Carcinogenesis; Cell Line, Tumor; Cell Transformation, Neoplastic; | 2020 |
Regulation of MFN2 by berberine alleviates obesity exacerbated colitis.
Topics: Animals; Berberine; Colitis; Dextran Sulfate; Diet, High-Fat; Endoplasmic Reticulum Chaperone BiP; E | 2020 |
Anticolitic Effect of Berberine in Rat Experimental Model: Impact of PGE2/p38 MAPK Pathways.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Catalase; Colitis; Dinoprostone; Interleukin-1beta; In | 2020 |
Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Caco-2 Cells; Colitis; Colon; Cytokines; Dextran Sulfa | 2021 |
Coptisine ameliorates DSS-induced ulcerative colitis via improving intestinal barrier dysfunction and suppressing inflammatory response.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Apoptosis Regulatory Proteins; Berberine; Colitis; Col | 2021 |
Micro- and Nanoencapsulated Hybrid Delivery System (MNEHDS): A Novel Approach for Colon-Targeted Oral Delivery of Berberine.
Topics: Administration, Oral; Animals; Berberine; Colitis; Colon; Delayed-Action Preparations; Dextran Sulfa | 2021 |
[Research progress of effect of berberine in treatment of ulcerative colitis based on cell signaling pathway].
Topics: Berberine; Colitis; Colitis, Ulcerative; Humans; Intestinal Mucosa; Signal Transduction | 2021 |
Berberine inhibits macrophage M1 polarization via AKT1/SOCS1/NF-κB signaling pathway to protect against DSS-induced colitis.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Cell Differentiation; Colitis; Cytokines; Dextran Sulf | 2018 |
Berberrubine attenuates mucosal lesions and inflammation in dextran sodium sulfate-induced colitis in mice.
Topics: Animals; Berberine; Colitis; Colon; Cytokines; Dextran Sulfate; Disease Models, Animal; Inflammation | 2018 |
Ginsenoside metabolite compound K promotes recovery of dextran sulfate sodium-induced colitis and inhibits inflammatory responses by suppressing NF-κB activation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Cell Line; Colitis; Colon; Cytokines; D | 2014 |
Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Base Sequence; Berberine; Clos | 2015 |
Berberine ameliorates TNBS induced colitis by inhibiting inflammatory responses and Th1/Th17 differentiation.
Topics: Animals; Berberine; Cell Differentiation; Colitis; Colon; Inflammation; Macrophages; Male; Mice, Inb | 2015 |
Berberine is a dopamine D1- and D2-like receptor antagonist and ameliorates experimentally induced colitis by suppressing innate and adaptive immune responses.
Topics: Adaptive Immunity; Animals; Benzazepines; Berberine; Bone Marrow; Colitis; Cytokines; Dendritic Cell | 2015 |
Berberine ameliorates chronic relapsing dextran sulfate sodium-induced colitis in C57BL/6 mice by suppressing Th17 responses.
Topics: Animals; Berberine; Cells, Cultured; Chronic Disease; Colitis; Colon; Dextran Sulfate; Disease Model | 2016 |
Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB activation.
Topics: Animals; Berberine; Colitis; Enterobacteriaceae; Enzyme Activation; HEK293 Cells; Humans; Inflammati | 2010 |
Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice.
Topics: Animals; Apoptosis; Berberine; Colitis; Colon; Cytokines; Dextran Sulfate; Disease Models, Animal; E | 2012 |
Suppressive effect of berberine on experimental dextran sulfate sodium-induced colitis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Berberine; Colitis; Cytokines; Dextran Sulf | 2012 |
The effect of berberine chloride on experimental colitis in rats in vivo and in vitro.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Cells, Cultured; Colitis; Colon; Interl | 2000 |